Connect with us



Biotechs target Alzheimer’s


A number of leading biotechnology companies are focussing their efforts on conquering Alzheimer’s.

Last week we reported M3 Biotechnology is developing a drug with the potential to halt the disease. And now global biopharmaceutical company, AbbVie, has announced it is investing more than $200 million in a deal with private biotech firm, Alector, to advance immuno-neurology therapies that harness the body’s immune system to fight the disorder.

“Alzheimer’s is among the most difficult-to-treat diseases and there is an urgent need for new scientific approaches that lead to better therapies for patients,” explained Dr Jim Sullivan, vice president, pharmaceutical discovery, AbbVie. “Alector’s unique approach to engaging the immune system to combat neurodegeneration reflects our commitment to target this epidemic in new ways. We recognized the potential of Alector’s research first as an AbbVie Ventures portfolio company and are now eager to partner with them to further develop this platform into meaningful advances for patients.”

The pair say they will work together to develop and commercialise the next generation of treatments in the fight against Alzheimer’s.

Newsletter Signup

Written By


Digital twin of the immune system will make precision medicine a reality


Saliva test for Alzheimer’s


Bill Gates’ fund targets Alzheimer’s


vaccine vaccine

New system could short circuit cancer


Newsletter Signup